a Melanocyte-stimulating hormone (aMSH) is a 13 amino acid peptide with potent anti-inflammatory effects. We created two DNA expression constructs (miniPOMC and pACTH1-17) that encode bioactive versions of the aMSH peptide, and tested these constructs for therapeutic effects in experimental autoimmune encephalomyelitis (EAE). Each construct contained the sequences for aMSH, as well as the sequences that are involved in the secretion and processing of the POMC gene with the assumption that these sequences would promote processing and release of the encoded aMSH peptide. The differences between the two constructs lie at the C-terminal end where amino acids necessary for amidation of aMSH were included in only the pACTH1-17 construct. These two constructs were tested in vitro in bioassays, and in vivo in a mouse model of EAE. The results show that although bioactive peptides are secreted from cells transfected with either construct, there appears to be a significant therapeutic effect only with the pACTH1-17 construct which contains the extra C-terminal amino acids. The data suggest that it is possible to engineer DNA expression vectors encoding small secreted peptides such as aMSH, and that similar type constructs may be useful as therapeutics for the treatment of inflammatory diseases.
Introduction a-Melanocyte-stimulating hormone (aMSH) is a 13 amino acid peptide derived from pro-opiomelanocortin (POMC). POMC is a pro-hormone that is post-translationally processed at paired basic residues to yield several biologically active peptide hormones, including adrenocortico-tropin (ACTH), aMSH, b-endorphin and gMSH. [1] [2] [3] The process that results in the generation of aMSH begins when POMC is directed to the lumen of the endoplasmic reticulum (ER) by the POMC signal peptide (amino acid residues . The sorting peptide (amino acid residues 27-52) subsequently directs POMC to secretion granules where it is further processed by pro-hormone convertase 1 (PC1) into the 39 amino acid peptide, ACTH (Figure 1 ). After the initial cleavage of POMC that creates ACTH, the first 17 amino acids of the ACTH peptide are then liberated by pro-hormone convertase 2 (PC2) to form the backbone of what will become native aMSH ( Figure 1) . 2, [4] [5] [6] The final steps in the production of native aMSH involve cleavage of ACTH1-17 to ACTH1-13, followed by amidation of the carboxyl terminus and acetylation of the amino terminus. The amidation modification requires a signal, located at amino acids 14-16 of ACTH (Gly, Lys, Lys; Figure 1 ). Like most other hormones and neuropeptides, the subsequent release of aMSH from the cell occurs in response to certain stimuli, although there is some level of constitutive secretion. 2, 7 Originally, it was thought that aMSH was produced primarily in the pituitary gland. More recently, the peptide has been found in several other regions of the brain and various peripheral organs including the skin. 8, 9 In fact, many cells are now known to produce aMSH, including keratinocytes, melanocytes, Langerhans cells, monocytes, macrophages, endothelial cells, fibroblasts and mast cells. 8, 9 aMSH has several known activities including the ability to stimulate melanogenesis, regulate body weight, and inhibit inflammation. [10] [11] [12] [13] [14] [15] These effects are mediated by cell surface, G-protein-coupled, melanocortin receptors (MC-R). [16] [17] [18] [19] aMSH binding to MC-R1 and MC-R5 activates adenyl cyclase and results in a significant increase of intracellular cAMP. 20, 21 In melanocytes this event up-regulates expression of tyrosinase, an enzyme that converts tyrosine to melanin. 22, 23 The antiinflammatory activity of aMSH is due in part to inhibition of IkB degradation, 24, 25 an effect that prevents the transcription factor nuclear factor kB (NF-kB) from entering the nucleus. NF-kB is required for the production of several pro-inflammatory factors, such as IL-1 and TNF-a 11, 12, 14, [26] [27] [28] , and has been shown to have a role in the pathogenesis of many inflammatory/autoimmune diseases. 25 The ability of aMSH to inhibit NF-kB translocation makes it an interesting target for therapeutic intervention. In fact, aMSH and its analogs have shown therapeutic activity in many animal disease models [11] [12] [13] [14] such as inflammatory bowel disease, 26 arthritis 29 and hepatitis. 27 However, the inherent instability of the peptide does not make it suitable for use as a therapeutic agent in humans. 30 In an effort to recognize the potential of aMSH as a drug for the treatment of disease, we have applied a DNA approach and have generated two DNA expression constructs that secrete bioactive peptides with aMSH activity. The POMC cDNA was not utilized to produce aMSH, since this would have resulted in the production of other bioactive peptides such as ACTH. Rather, sequences from the POMC gene involved in the secretion, processing, and post-translational modification of the pre-pro-hormone were included in two constructs (miniPOMC and pACTH1-17) in order to promote production solely of biologically active aMSH.
28,31
Transfection of cells with either of the constructs resulted in the production of secreted peptide with aMSH activities that could be detected by a variety of assays. When the constructs were tested in mice with EAE, there were observable changes in the kinetics and severity of the disease that reinforced the observation that these constructs produced bioactive peptides. These data also support the utility of a DNA-based approach for the therapeutic use of aMSH in inflammatory disease.
Results

Generation of aMSH expression constructs
The goal for the first part of these studies was to create DNA expression constructs that produce a secreted peptide with aMSH bioactivity. Creating a construct to secrete a single small peptide in the absence of a propeptide backbone is inherently difficult for reasons of RNA stability as well as the lack of normal posttranslational processing and intra-cellular trafficking signals. Inclusion of the entire pro-peptide POMC coding sequence was not a viable solution as this would result in the unwanted production of additional neuropeptides. In an effort to optimize expression and secretion of peptides with aMSH activity, a DNA construct was generated that contains elements of the native POMC responsible for intra-cellular trafficking and processing. These include a signal sequence, sorting sequence, partial junctional peptide and sequences that encode aMSH. This basic construct was named miniPOMC (Figure 2 ). The ACTH1-17 construct includes all of the miniPOMC sequences and an additional three amino acid residues that are essential for the amidation of ACTH1-13 and the production of native aMSH (Figure 1 ).
Bioactive aMSH is secreted by cells transfected with aMSH encoding constructs
One activity associated with aMSH is the induction of melanin synthesis by melanocytes, and we have used an established assay to measure this with the B16/F10 melanoma cell line. When B16/F10 cells are cultured in the presence of increasing concentrations of native synthetic aMSH peptide, the amount of melanin production is increased due to a darkening of the cell supernatant which is detected by absorbance reading at 405 nm (Figure 3a) . Non-amidated forms of the synthetic aMSH peptide are not as effective as the amidated version in promoting melanin production, although Acetyl transferase Figure 1 Schematic diagram of POMC processing. ACTH 1-39 is generated from POMC by PC1 cleavage. It is further cleaved at basic residues to yield ACTH1-17 and then to ACTH 1-14 by PC2. Peptidylglycine alpha-amidating monooxygenase converts ACTH 1-14 to aMSH by removing Gly14 and amidating the C-terminus. Finally, the peptide is acetylated at the amino terminus to produce native aMSH. The nucleotide and amino acid sequences of the miniPOMC coding sequences including the signal peptide, sorting peptide, partial junction peptide and aMSH sequences (underlined). For the extended aMSH expression construct, pACTH1-17, the sequence encoding GlyLysLysArg was added before the stop codon.
Gene therapy using aMSH expression constructs P Yin et al inclusion of the amino acid amidation signal sequence in a synthetic peptide appears to boost activity ( Figure 3a) . A melanin assay was also performed to determine if the B16/F10 cells transfected with either of the two aMSH DNA constructs produced peptides with aMSH bioactivity. Supernatants from transfected cells were added to untransfected B16/F10 cells and melanin production was measured. The supernatants from cells transfected with miniPOMC or pACTH1-17 expression constructs promoted significant melanin production in untransfected cells as compared to the supernatants from cells transfected with vector alone (Figure 3b) . Interestingly, the supernatants from cells transfected with the pACTH1-17 construct were more active than those from cells transfected with the miniPOMC construct.
Products generated from aMSH expression constructs can inhibit NF-kB activation NF-kB is a major transcription factor that up-regulates expression of several pro-inflammatory factors, such as TNF-a and interferon-g. aMSH has been shown to inhibit the translocation of NF-kB to the nucleus to result in decreased expression of pro-inflammatory cytokines. 24 Two separate assays were performed to test whether the peptides generated from the aMSH expression constructs were able to inhibit NF-kB translocation. In the first assay, vector control or either of the two aMSH expression constructs were co-transfected into RAW cells together with an NF-kB-dependent luciferase reporter construct. RAW, rather than B16/F10 cells, were used because NF-kB is not effectively and reproducibly stimulated by LPS or TNF-a in melanocytes (data not shown). Following activation of NF-kB by LPS treatment of transfected RAW cells, cell lysates were prepared and assayed for luciferase expression. Luciferase expression is reported as the fold increase in luciferase activity in LPS treated versus untreated cells, as measured for cells transfected with each DNA construct. The fold induction of NF-kB in the RAW cells transfected with the empty vector control was set at 100 for purposes of comparison. Co-transfection of cells with the reporter construct and either of the aMSH expression constructs resulted in a significant reduction in luciferase activity relative to cells transfected with vector control (Figure 4a ). These data provide further evidence that both of the aMSH expression constructs produce peptides with aMSH activity.
The second assay used to detect a reduction in NF-kB activity was the Trans-AMt NF-kB ELISA. This assay measures binding of NF-kB from cell lysates to an immobilized oligonucleotide containing the NF-kB binding site. RAW cells, transfected and activated as above, were lysed and the amount of bound NF-kB activity measured from cells transfected with vector control was set to 100 for purposes of comparison. Co-transfection of cells with the reporter construct and either of the aMSH expression constructs resulted in a significant reduction in NF-kB binding relative to cells transfected with vector. The results of these two assays demonstrate that peptides generated from both aMSH expression constructs are able to inhibit NF-kB activation.
Intra-muscular injection of the constructs leads to delayed onset and reduced severity of EAE Groups of 10 PLJ Â SJ/l F1 mice immunized with guinea pig myelin basic protein (gpMBP) to induce experimental autoimmune encephalomyelitis (EAE) were injected with 100 mg of either vector, miniPOMC, or pACTH1-17. The plasmids were injected intra-muscularly into the tibilias, once per week, for 4 weeks on days 0, 7, 14, and 21. The EAE induced in these experiments is a relapsingremitting form that results in a relatively severe form of the disease, and disease in the mice was scored daily starting on day 8 through day 28 (7 days after final DNA injection). The results show that both the miniPOMC and pACTH1-17 constructs did reduce the mean clinical Gene therapy using aMSH expression constructs P Yin et al score of the disease. The data shown in Figure 5a are representative of three separate experiments performed with miniPOMC and they show a slight, but statistically insignificant reduction of clinical scores from day 16 to day 28. The lower clinical scores observed in these experiments are likely due to a reduction in mortality observed in mice treated with miniPOMC ( Table 1 ). The data shown in Figure 5b are representative of one of five separate experiments performed with pACTH1-17, and they indicate statistically significant reductions in the clinical scores of treated mice on days 12-16. This early reduction in clinical score was due to the fact that the disease onset was delayed in these mice. As shown in Table 1 , the onset of disease was significantly delayed in five experiments by the treatment of mice with the pACTH1-17 plasmid. The treated mice also show a reduced mortality relative to mice injected with saline or empty vector.
Discussion
The experiments described herein were performed with an intent to develop DNA expression constructs that permit secretion of peptides with aMSH bioactivity and then to test them in an animal model of autoimmunity.
The data demonstrate that inclusion of the minimal endogenous POMC trafficking signals in frame with sequences that encode ACTH1-13 or ACTH1-17 can direct expression and secretion of peptides with aMSH activity. The peptides are expressed by melanocytes (B16/F10) and macrophages (RAW) in vitro and have the expected melanin stimulating activity and effect on NFkB activation. Furthermore, the supernatant of cells transfected with expression vectors that encode the minimal trafficking signals in frame with ACTH1-17 demonstrated enhancement of both these activities. The front end of the miniPOMC sequence, including the signal, sorting and junctional peptides, may be cleaved from the encoded peptides to liberate peptides including, but not necessarily limited to, the ACTH1-13 sequence. The signal sequence, which is expected to direct all versions of the miniPOMC peptides to the ER is likely cleaved to liberate a peptide that includes the sorting signal, junctional peptide and ACTH1-13 sequences. The sorting signal, which directs the peptide to the secretory vesicles, and the junctional peptide should be removed in the vesicles to liberate ACTH1-13. The fact that muscle cells produce a bioactive peptide when transfected with the miniPOMC vectors (data not shown) indicates that non-secretory cells either have the capacity to perform processing of the sorting and junctional peptides, or that this event is not necessary for activity.
Signals in the ACTH1-17 peptide, at positions 14-16 (Gly, Lys, Lys), are responsible for the amidation of ACTH1-13. The peptides secreted by the miniPOMC vector are unlikely to be amidated since they do not have this signal. However, the peptide expressed from the pACTH1-17 construct is more likely to be processed and Gene therapy using aMSH expression constructs P Yin et al amidated to produce a peptide with a C-terminus identical to native aMSH. Amidated aMSH is more active than the non-amidated peptide (Figure 3a) . Since the peptide generated from pACTH1-17 seems to have enhanced aMSH activity in the melanin bioassay and in vivo models, this suggests that the expressed peptide may well be amidated. However, we cannot rule out other possibilities for enhanced activity, such as stability differences between peptides generated from miniPOMC and pACTH1-17. Efforts to pinpoint the exact nature of the peptide secreted by cells expressing these constructs have been unsuccessful. Tested methods include Western blot analysis, HPLC and mass spectrometry. Western blot analysis with synthetic aMSH required nanogram levels for detection (data not shown), and it is likely that the peptide concentration in supernatants of transfected cells was not high enough for detection by this assay. Concentration of the supernatant by column chromatography and detection by mass spectrometry also proved difficult as the active peptide degraded and oxidized during the purification process.
The anti-inflammatory properties of aMSH are numerous. The peptide acts through cell surface receptors to reduce production of pro-inflammatory mediators, such as TNF-a, nitric oxide, IL-1 and IL-6.
27,32 Such downregulation is due to the inhibition of NF-kB activity, 24, 25 and this activity suggests that a therapeutic opportunity may exist for aMSH. The peptide is safe when given in large and consistent doses to animals or humans. 26, 27, 29 However, it is very unstable in vivo and therapeutic use would require daily administration. 26 , to increase activity and stability relative to native aMSH. Some of these peptides are currently being tested in clinical trials. 35, 36 A DNA-based therapeutic could reduce the need for daily administration and provide for long-term production of aMSH. The first step towards this goal was to test these constructs in an animal model of inflammation/ autoimmunity. Interestingly, the construct that had the strongest and the most consistent therapeutic effect in vivo was pACTH1-17. We are intrigued by the possibility that the enhanced effect of this plasmid may be due to amidation, but we have not yet been able to detect peptides expressed from these constructs to test this theory. We are currently continuing in these efforts.
In summary, two aMSH expression constructs have been generated and express peptides with aMSH activities in cell lines following transfection with plasmid DNA. The encoded peptides inhibit NF-kB activation, a transcription factor essential for the production of inflammatory cytokines. One of the constructs, pACTH1-17, was shown to decrease disease severity in a mouse model of autoimmunity. Collectively, these data support the notion that DNA expression vectors can be created to direct the expression and secretion of small peptides and that their activities can have therapeutic effects. It will be interesting to try this approach for other peptides with inherent stability issues. One possible candidate is vasoactive intestinal peptide (VIP), a peptide recently shown to inhibit symptoms in an animal model of rheumatoid arthritis. 37 
Materials and methods
Cell culture B16/F10 mouse melanocyte cells and RAW 267. 4, a mouse macrophage cell line, were obtained from ATCC (ATCC, Manassas, VA, USA). The cells were grown at 37 o C in Dulbecco's modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum (JRH Biosciences, Lenexa, KS) in a humidified incubator at 5% CO 2 . Cells were split every other day.
Construction of aMSH expression vectors
All oligonucleotides were purchased from Operon (Alameda, CA, USA). Complementary oligonucleotides encoding the human POMC signal peptide, sorting peptide, partial junction peptide and aMSH were created based upon the human POMC cDNA sequence (NM_000939, Genebank; Figure 2 ). The restriction enzyme sites, HindIII, BssHII upstream of the start codon and BamHI, Xhol downstream of the stop codon, were added for cloning purposes. The synthesized oligonucleotides were annealed and cloned into the HindIII and Xhol sites of pCMV-Script (Stratagene, La Jolla, CA, USA), a mammalian expression vector containing a CMV Mean day onset was calculated by averaging the experimental day the first symptoms appeared in each mouse within the treatment group. Mortality is shown as the number of mice that died by day 28. Incidence is at or near 100% for all groups.
Gene therapy using aMSH expression constructs P Yin et al immediate early promoter and SV40 polyadenylation sequence, to generate miniPOMC. A pair of oligonucleotides was utilized to generate the extended miniPOMC construct, pACTH1-17. The top strand oligonucleotide contains the HindIII site and sequence corresponding to the 5 0 end of the miniPOMC sequence. The bottom strand oligonucleotide has complementary sequences to the 3 0 end of the miniPOMC sequence, which adds a four amino acid extension before the stop codon ACTH1-17 (GGC AAG AAG CGG). The extended miniPOMC insert was generated by PCR using the pair of oligonucleotides indicated above and mini-POMC as a template. The newly synthesized insert was subcloned into pCMV-Script using HindIII and Xhol to generate pACTH1-17. All constructs were sequenced to ensure correctness.
Melanin assay
B16/F10 cells were plated into 6-well plates at a concentration of 1 Â 10 5 cells/ml, 2 ml per well. Cells were incubated at 371C overnight. The following day, 3.5 mg of the aMSH expression construct or vector control and 0.5 mg of secreted embryonic alkaline phosphatase (SEAP) expression construct as a transfection efficiency control (Gene Therapy Systems, San Diego, CA, USA) were mixed with 15 ml lipofectamine (Gibco, Carlsbad, CA, USA) and added to the cells. Mock-transfected samples received lipofectamine and no DNA. After 24 h, transfection reagents were removed and replaced with fresh media. Cells were incubated for two additional days. The supernatants were collected and tested in the SEAP and melanin assays.
The SEAP assay was performed according to the manufacturer's instructions (Gene Therapy Systems, San Diego, CA, USA). Supernatants from transfected cells were heated at 651C for 30 min to inactivate endogenous alkaline phosphatase activity. The SEAP activity was quantitatively determined by using a colorimetric assay based on hydrolysis of the chromogenic substrate paranitrophenyl phosphate (PNPP; Phospha-light assay system, TROPIX, Foster City, CA, USA). To start the enzymatic reaction, 200 ml of the PNPP substrate was added to each sample. The reaction was allowed to stand at room temperature for 30 min prior to analysis. Absorbance at 405 nm of each sample was then determined.
For the melanin assay, B16/F10 cells seeded in 96-well plates at 2.5 Â 10 4 cells/ml, 100 ml per well were incubated at 371C overnight. Supernatants containing synthetic peptides or from DNA-transfected cells were then added. The synthetic peptides included acetylated, amidated aMSH, acetylated, non-amidated aMSH or acetylated, non-amidated ACTH1-17 (BACHEM, Torrance, CA, USA) at different concentrations. Then, cells were incubated at 371C for an additional 4 days. Melanin production (which turned the cells and the supernatant dark to black) was measured by absorbance at 405 nm. These numbers were then normalized based upon transfection efficiency using SEAP as a control.
Luciferase assay
A total of 8 Â 10 6 RAW cells in 400 ml DMEM medium were electroporated with pNF-kB-Luc plasmid (Clontech, Palo Alto, CA, USA), an aMSH expression vector or vector control, and the SEAP expression vector at a ratio of 1.5 mg:1. 5 mg:0.5 mg, respectively. The electroporation was performed with a Bio-Rad gene pulser at a setting of 200 V and 960 mF. Cells were incubated for 24 h in phenol-red-free DMEM (Gibco, Carlsbad, CA, USA) after electroporation. Cells were then stimulated with LPS at a concentration of 10 mg/ml (Sigma, St. Louis, MO, USA) for 4 h to activate NF-kB. Culture medium was collected and the SEAP assay was performed as described above. Cells were lysed with 1 Â reporter lysis buffer and assayed for luciferase activity according to the manufacturer's directions (Luciferase assay kit; Promega, Madison, WI, USA). For each expression vector, fold induction of luciferase expression was calculated as the ratio of SEAP normalized luciferase activity from LPS-treated cells to SEAP normalized luciferase activity from untreated cells. Then, fold induction of luciferase expression in the cells transfected with empty vector was set as 100%. By comparing with this value, the percentage fold induction in the cells transfected with expression constructs were calculated accordingly.
Trans-AM NF-kB ELISA
The protein concentration of cell lysates in 1X reporter lysis buffer was measured by Bradford assay. Equal amounts of protein from lysates were used to determine the binding activity of NF-kB using the Trans-AM NF-kB ELISA kit (Active Motif; Carlsbad, CA, USA). The assay was carried out as described. Briefly, cell lysates were incubated in wells of a 96-well plate that had been coated with oligonucleotides containing the NFkB consensus binding site. The plates were washed, anti-p65 antibody specific for NFkB bound to DNA was added, and the samples were incubated at room temperature for 1 h. The secondary antibody coupled with horse radish peroxidase was then added and the samples were incubated for 1 h at room temperature. Following color development, the samples were quantified by spectrophotometry at OD450. Fold induction of NFkB binding was calculated as the ratio of spectrophotometric reading from LPS-induced cells to that of un-induced cells for each expression vector. Then, fold induction of NFkB binding in the cells transfected with empty vector was set as 100%. By comparing with this value, the percentage fold induction in the cells transfected with expression constructs were calculated accordingly.
Induction of EAE
On day 0, female PL/J Â SJL mice (The Jackson Laboratory, Bar Harbor, Maine, USA) were immunized subcutaneously at the base of the tail with 300 mg guinea pig myelin basic protein emulsified in incomplete Freund's adjuvant containing 2 mg/ml Mycobacterium tuberculosis H37 RA (all reagents were from Sigma, St Louis, MO, USA). On days 0, 2 and 7 400 ng of Pertussis Toxin (List Biologicals, Campbell, CA) was administered intraperitoneally. Groups consisted of 10 mice per group and disease was scored daily beginning on day 8 using the following standard scale: 38 0 normal mouse, no overt signs of disease; 1 limp tail or hind limb weakness, but not both; 2 limp tail and hind leg weakness; 3 partial hind leg paralysis;
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Treatment with aMSH producing plasmid
Plasmid DNA, 100 mg, containing either vector alone (pCMV-Script) or vector containing the miniPOMC or pACTH1-17 constructs were injected intra-muscularly on days 0, 7, 14 and 21. The total volume injected was 100 ml. The muscle used was the tibilias (50 ml/ muscle). Experiments were performed under a protocol approved by the Animal Care and Use Committee.
